Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy

Abstract

The American Society for Transplantation and Cellular Therapy (ASTCT) published its first white paper on indications for autologous and allogeneic hematopoietic cell transplantation (HCT) in 2015. It was identified at the time that periodic updates of indications would be required to stay abreast with state of the art and emerging indications and therapy. In recent years the field has not only seen an improvement in transplantation technology, thus widening the therapeutic scope of HCT, but additionally a whole new treatment strategy using modified immune effector cells, including chimeric antigen receptor T cells and engineered T-cell receptors, has emerged. The guidelines review committee of the ASTCT deemed it optimal to update the ASTCT recommendations for indications for HCT to include new data and to incorporate indications for immune effector cell therapy (IECT) where appropriate. The guidelines committee established a multiple stakeholder task force consisting of transplant experts, payer representatives, and a patient advocate to provide guidance on indications for HCT and IECT. This article presents the updated recommendations from the ASTCT on indications for HCT and IECT. Indications for HCT/IECT were categorized as (1) Standard of care, where indication is well defined and supported by evidence; (2) Standard of care, clinical evidence available, where large clinical trials and observational studies are not available but have been shown to be effective therapy; (3) Standard of care, rare indication, for rare diseases where demonstrated effectiveness exists but large clinical trials and observational studies are not feasible; (4) Developmental, for diseases where preclinical and/or early-phase clinical studies show HCT/IECT to be a promising treatment option; and (5) Not generally recommended, where available evidence does not support the routine use of HCT/IECT. The ASTCT will continue to periodically review these guidelines and update them as new evidence becomes available.

Female sex as an independent prognostic factor in the development of oral mucositis during autologous peripheral stem cell transplantation

“…There is a rise in incidence of malignant haematological diseases. Autologous and allogeneic haematopoietic stem cell transplantations (HSCT) are used with increasing frequency and efficiency as a therapy 1 . High-dose intensive cytostatic treatment and in some cases total body irradiation (TBI) is employed as part of the transplantation process (myeloablative conditioning therapy).…”

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?

“…The most common indications for allo-HCT in adults are acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (127). Despite the toxicities associated with the transplant itself, relapse remains the most significant cause of treatment failure and death after allo-HCT, highlighting the need for further disease-modifying innovation without added toxicity (128)(129)(130).…”

COVID-19 et greffe de cellules souches hématopoïétiques : recommandations et situation au Maroc

“…Malgré la stabilisation de l'épidémie et le nombre de nouveaux cas à moins de 200 cas par jour, des mesures de précautions drastiques sont toujours prises par notre ministère de Santé pour limiter la propagation du virus avec la création d'unités dédiées au COVID- 19 [8]. La greffe de CSH, allogénique et autologue, est une thérapeutique incontournable de traitement des maladies graves, congénitales ou acquises de l'hématopoïèse, ainsi que des principaux cancers [9,10] mais pourvoyeuse d'une importante morbi-mortalité secondaire à la toxicité du conditionnement administré, à la réaction du greffon contre l'hôte et au déficit immunitaire post-greffe [11,12]. De ce fait, ces patients sont à très haut risque pendant cette période d'épidémie virale.…”